Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

0.9586
+0.05576.17%
Post-market: 0.9500-0.0086-0.90%19:59 EDT
Volume:935.53K
Turnover:865.38K
Market Cap:4.25M
PE:-0.03
High:0.9789
Open:0.9100
Low:0.8720
Close:0.9029
Loading ...

Allarity announces expansion of Phase 2 trial on stenoparib

TIPRANKS
·
06 Feb

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

THOMSON REUTERS
·
06 Feb

Allarity Therapeutics Inc - Patient Enrollment Expected to Begin in First Half of 2025

THOMSON REUTERS
·
06 Feb

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle With SEC

THOMSON REUTERS
·
30 Jan

BRIEF-Allarity Therapeutics To Pay $2.5 Million Civil Penalty

Reuters
·
30 Jan

Allarity Therapeutics Inc - to Pay $2.5 Million Civil Penalty

THOMSON REUTERS
·
30 Jan

Allarity Therapeutics Inc: Has Reached an Agreement in Principle With the SEC Staff to Resolve the Investigation With Respect to the Co

THOMSON REUTERS
·
30 Jan

Allarity reports progress in Phase 2 stenoparib trial

TIPRANKS
·
18 Nov 2024

BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial

Reuters
·
18 Nov 2024

Allarity Therapeutics Inc - Maintains Cash Balance of $18.5 Million

THOMSON REUTERS
·
18 Nov 2024

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

THOMSON REUTERS
·
18 Nov 2024

Allarity Therapeutics Inc - Two Patients Exceed 14 Months on Treatment in Phase 2 Trial

THOMSON REUTERS
·
18 Nov 2024

Allarity reports Q3 EPS ($7.71)

TIPRANKS
·
14 Nov 2024

Allarity Therapeutics Inc: Qtrly Loss per Share $7.71

THOMSON REUTERS
·
14 Nov 2024

BRIEF-Allarity Therapeutics To Be Granted European Patent For Drp Companion Diagnostic For Stenoparib

Reuters
·
22 Oct 2024

Allarity granted EPO for DRP companion diagnostic for stenoparib

TIPRANKS
·
22 Oct 2024